

CURRICULUM VITAE

Alex S. Befeler, M.D.

A. PERSONAL INFORMATION

Office Address: 3635 Vista @ Grand Ave FDT 9S
St. Louis, MO 63110
Marital Status: Married
Place of Birth: Cleveland, Ohio

B. EDUCATION AND TRAINING

1984-1988 BA, The College at the University of Chicago, Chicago, IL
1988-1992 MD, University of Chicago Pritzker School of Medicine, Chicago, IL
1992-1995 Resident, Internal Medicine, University of Texas Southwestern Medical Center,
Dallas, TX
1995-1997 Fellow in Gastroenterology, University of Chicago Hospitals, Chicago, IL
1997-1998 Fellow in Hepatology, University of Chicago Hospitals, Chicago, IL
2001-present MPH (in progress), Saint Louis University

C. BOARD CERTIFICATION AND LICENSURE

BOARD CERTIFICATION:

National Board of Medical Examiners Diplomat	No., 1992
American Board of Internal Medicine Diplomat in Internal Medicine	No., 1995
Diplomat in Gastroenterology	No., 1997

LICENSURE:

Missouri State Board of Registration for the Healing Arts	No. , 1998
Illinois Department of Regulations	No. , 1995

D. CURRENT POSITION AND ADDRESS

Associate Professor of Internal Medicine
Medical Director for Liver Transplantation
Division of Gastroenterology and Hepatology
Saint Louis University School of Medicine
3635 Vista Avenue at Grand Blvd.
P.O. Box 15250
E-Mail: befelera@slu.edu
abefeler@gmail.com

E. PREVIOUS PROFESSIONAL EXPERIENCE

- 1998-2005 Assistant Professor of Internal Medicine, Division of Gastroenterology and Hepatology, Saint Louis University Medical Center, St. Louis, MO
- 2005-present Associate Professor of Internal Medicine, Division of Gastroenterology and Hepatology, Saint Louis University Medical Center, St. Louis, MO
- 2006-present Medical Director, Liver Transplantation, Division of Gastroenterology and Hepatology, Saint Louis University Medical Center, St. Louis, MO

F. CLINICAL STAFF APPOINTMENTS

Saint Louis University Hospital
 St. Mary's Hospital
 Marshall Browning Hospital
 Saint Louis University Cancer Center

G. PROFESSIONAL SOCIETY MEMBERSHIPS

- American Association for the Study of Liver Diseases
 Liver Transplantation and Surgery Committee
 Abstract Reviewer for Digestive Disease Week and the Liver Meeting
- Liver Cancer Research Network
 Founding member
 Chairman, Steering Committee
- Cancer Prevention Network
 Member, Steering Committee – hepatobiliary representative
- Mid-America Transplant Services
 Medical Affairs Committee Member

H. HONORARY SOCIETIES, HONORS AND AWARDS:

- 1998 General honors, Biology, University of Chicago
- 2001 AASLD Jan Albrecht Commitment to Clinical Research in Liver Disease Award (Physician clinical research development award) Project: A randomized placebo controlled trial of isotretinoin in the chemoprevention of hepatocellular carcinoma.
- 2002 AASLD Young Clinical Scholar Award to World Congress of Gastroenterology
- 2002 Junior Faculty Career Development Award, Saint Louis University School of Medicine

I. PROFESSIONAL SERVICES**REVIEWER FOR SCIENTIFIC JOURNALS:**

American Journal of Gastroenterology
Hepatology
Journal of Hepatology

J. RESEARCH SUPPORT:

Federal Funding:

1. NCI RFP N01-CN25000-39. Phase I and Phase II Clinical Trials of Cancer Chemopreventive Agents; principal investigator: Charles L. Loprinzi, M.D.; effort 5%; entire period of support 8/01/03 – 7/31/05; Cancer Prevention Network, Hepatobiliary representative to steering committee: Alex Befeler
2. NIDDK RO1 DK 56924-01A2. Randomized Trial of High Dose Urso in PSC: principal investigator Keith Lindor; effort 5%; entire period of support 9/01/01-8/31/04; direct costs \$132,432. Saint Louis University principal investigator: Alex Befeler
3. NIDDK UO1 CA 084986. Validation of Serum Markers for the Early Detection of Hepatocellular Carcinoma. NCI EDRN; principal investigator: Jorge Marrero; effort 5%; entire period of support 12/01/04 – 11/30/06; direct costs \$35,800. Saint Louis University principal investigator: Alex Befeler

Saint Louis University Funding

1. Liver Cancer Research Network (establishment of a multicenter national outcomes database on patients with hepatocellular carcinoma) Principal investigator: Alex Befeler
2. When a Cure Isn't Possible. Development of a quality of life instrument for patients with incurable liver cancer; principal investigator : Alex Befeler Saint Louis University Liver Center; direct casts \$27,700
3. Mycophenolate mofetil (MMF) for Autoimmune Hepatitis Principal Investigator: Alex Befeler

Pharmaceutical Studies:

1. A Randomized, Open-Label, Comparative Evaluation of Conversion from Calcineurin Inhibitor Treatment to Sirolimus Treatment versus Continued Calcineurin Inhibitor Treatment in liver Allograft Recipients undergoing Maintenance Therapy. Wyeth Research Protocol 0468H1-313-US. Principal investigator Saint Louis University: Alex Befeler; direct costs \$296,026.
2. A phase II, randomized, placebo-controlled study of Bay 43-9006 (Sorafenib) in patients with advanced hepatocellular carcinoma (HCC) Bayer Healthcare Pharmaceuticals Corporation 100554. Principal Investigator Saint Louis University: Alex Befeler; direct costs. \$87,172.
3. A double blind placebo controlled randomized phase III study of intravenous terlipressin in patients with type I hepatorenal syndrome. Orphan Therapeutics Protocol 68582. Principal Investigator: Alex Befeler direct costs \$37,000.

K. BIBLIOGRAPHY

ORIGINAL, BASIC, AND CLINICAL INVESTIGATION

1. **Befeler AS**, Schiano TD, Conjeevaram H, KA Dasgupta, JM Millis, Baker AL, Lisssoos TW. Management of inflammatory bowel disease after liver transplantation. *Transplantation* 1998;65:393-396.

2. Conjeevaram HS, Hart J, Dasgupta K, Lissos T, Schiano T, Millis M, **Befeler AS**, Baker AL. Rapidly progressive liver injury and fatal alcoholic hepatitis occurring after liver transplantation in alcoholic patients. *Transplantation* 1999;67:1562-1568.
3. **Befeler AS**, Schiano TD, Lissos TW, Conjeevaram HS, Anderson AS, Millis JM, Albertucci M, Baker AL. Successful combined liver-heart transplantation in adults: Report of three patients and review of the literature. *Transplantation* 1999;68:1423-1427.
4. Diwakaran HH, **Befeler AS**, Britton RS, Brunt EM, Bacon BR. Hereditary hemochromatosis patients with hepatitis C present with advanced hepatic fibrosis at a younger age and at a lower hepatic iron concentration. *Journal of Hepatology* 2002;36:687-691.
5. Di Bisceglie AM, Lyra AC, Schwartz M, Reddy RK, Martin P, Gores G, Lok ASF, Hussain KB, Gish R, van Thiel DH, Younossi Z, Tong M, Hassanein T, Balart L, Fleckenstein J, Flamm S, Blei A, **Befeler AS**, Liver Cancer Network. Hepatitis C-related hepatocellular carcinoma in the United States: Influence of ethnic status. *American Journal of Gastroenterology* 2003;98:2060-2063.
6. **Befeler AS**, Palmer DE, Hoffman M, Longo W, Solomon H, Di Bisceglie AM. The safety of intra-abdominal surgery in cirrhotics: MELD is superior to Child-Turcotte-Pugh in predicting outcome. *Archives of Surgery* 2005;140:650-654.

REVIEWS, CHAPTERS IN BOOKS OR PROCEEDINGS, EDITORIALS

1. **Befeler AS**, Saeed ZA. Management of bleeding varices. In: Bacon BR and Di Bisceglie AM eds. *Liver Disease: Diagnosis and Management*. Philadelphia: W.B. Saunders; 2000;419-434.
2. **Befeler AS**, Di Bisceglie AM. Hepatitis B. *Infectious Disease Clinics of North America* 2000;14:617-632.
3. **Befeler AS**, Di Bisceglie AM. Treatment of hepatocellular carcinoma. In: Tabor E ed. *Perspectives in Medical Virology, Viruses in Liver Cancer* 2002.
4. **Befeler AS**, Di Bisceglie AM. Hepatocellular carcinoma: Diagnosis and treatment *Gastroenterology* 2002;122:1609-1619.
5. Di Bisceglie AM, **Befeler AS**. Cystic and nodular diseases on the liver. In Schiff ER, Maddrey, WC, and Sorell, M eds. *Schiff's Diseases of the Liver Ninth Edition*. Philadelphia: Lippincott Williams and Wilkins, 2003, p1149-1167.
6. **Befeler AS**. New developments in hepatocellular carcinoma. *Medscape* www.medscape.com/viewarticle.1464173, 2003.
7. Fecht W, **Befeler AS**. Prevention of hepatocellular carcinoma. *Current Gastroenterology Reports* 2004;6:37-43.
8. **Befeler AS**. Clinical developments in hepatocellular carcinoma. *Medscape* <http://www.medscape.com/viewarticle/495214>, 2004.
9. **Befeler AS**. Chemoembolization and bland embolization: A critical appraisal. *Clinics in Liver Disease* 2005;9:287-300.

10. **Befeler AS**, Hayashi PH, Di Bisceglie AM. Liver transplantation for hepatocellular carcinoma. *Gastroenterology* 2005;128:1752-1764.
11. Di Bisceglie AM, **Befeler AS**. Cystic and nodular diseases on the liver. In Schiff ER, Maddrey, WC, and Sorell, M eds. *Schiff's Diseases of the Liver Tenth Edition*. Philadelphia: Lippincott Williams and Wilkins 2007, p1231-1251.
12. **Befeler AS**. Complications of cirrhosis: New developments in hepatocellular carcinoma. *Medscape* <http://www.medscape.com/viewarticle/518705>, 2005.
13. Smith T, **Befeler AS**. High-Dose ursodeoxycholic acid for the treatment of primary sclerosing cholangitis. *Current Gastro Reports* 2007 (in press).

ABSTRACTS

1. Veraja LA, Belsito A, **Befeler AS**, Weinstein D, Sackner MA. Respiratory inductive plethysmography derived gas exchange measurements at rest and exercise. *Am Rev Respir Dis* 1986;133:A28.
2. Suarez M, Bizousky F, **Befeler AS**, Sackner MA. Performance of mercury in silastic strain gauges and respiratory inductive plethysmography assessed with spirometry. *Am Rev Respir Dis* 1987;135:A49.
3. Suarez M, Bizousky F, **Befeler AS**, Sackner MA. Inspiratory pause to enhance gas delivery to lungs during mechanical ventilation when high inflation pressures occur. *Am Rev Respir Dis* 1987;135:A201.
4. **Befeler AS**, Piper J, Millis M, Hart J, Dasgupta K, Baker A, Conjeevaram H. Short and long term outcome of patients with hepatocellular carcinoma undergoing liver transplantation. *Hepatology* 1996;24:482A.
5. **Befeler AS**, Ehrenpreis E, Bissonnette M, Xiao SY. Metastatic gastrinoma presenting as a giant duodenal ulcer with massive upper gastrointestinal bleeding. *Am J Gastroenterol* 1997;92:1695.
6. **Befeler AS**, Schiano TD, Lissos TW, Conjeevaram H, Millis JM, Newell KA, Thistlethwaite JR, Albertucci M, Baker AL. Successful combined heart-liver transplantation in adults. *Hepatology* 1997;26:480A.
7. Conjeevaram HS, Hart J, Dasgupta K, Lissos T, Schiano T, Millis M, **Befeler AS**, Baker AL. Fatal alcoholic hepatitis and rapidly progressive liver injury occurring after liver transplantation in alcoholics. *Gastroenterology* 1997;112:A1247.
8. Solomon H, Kane R, Garvin P, Ramrakhiani S, **Befeler AS**, Burton FR, Mistry B, Glockner J, Wolverson M, Bacon BR, Varma C. Portal vein arterialization (PVA) in liver transplantation. *ITLS*, Pittsburgh August 1999.
9. Ali A, **Befeler AS**, Bacon BR, Varma C, Solomon H, Ramrakhiani S. Hyperhomocysteinemia in liver transplant recipients. *Transplantation* 2000;69:S391.
10. Ramrakhiani S, **Befeler AS**, Ali A, Varma C, Solomon H, Bacon BR. Safety and efficacy of hepatitis A vaccine in liver transplant recipients. *Transplantation* 2000;69:S319.

11. Diwakaram HH, **Befeler AS**, Britton RS, Brunt EM, Bacon BR. Hereditary hemochromatosis patients with hepatitis C present with advanced hepatic fibrosis at a younger age and at a lower hepatic iron concentration. *Gastroenterology* 2000;118:A997.
12. Sponseller CA, Ramrakhiani S, **Befeler AS**. Does the Mayo Clinic endstage liver disease model (MELD) accurately allocate organs to 2A patients? *Gastroenterology* 2001;120:A77.
13. Ramrakhiani S, **Befeler AS**, Bacon BR. Dyslipidemia and other major coronary risk factors in liver transplant recipients. *Gastroenterology* 2001;120:A562.
14. Habib A, Bacon BR, **Befeler AS**, Ramrakhiani S. Rapamycin for treatment of renal insufficiency related to calcineurin inhibitors in liver transplant recipients. *Gastroenterology* 2001;120:A-92.
15. Ramrakhiani S, **Befeler AS**, Bacon BR. Nonalcoholic steatohepatitis is associated with increased histological activity and fibrosis in patients with chronic hepatitis C. *Gastroenterology* 2001;120:A543.
16. Ramrakhiani C, Bacon BR, **Befeler AS**, Ramrakhiani S, Labovitz AJ. 2-D and dobutamine stress echocardiography in the pre-operative evaluation of patients undergoing orthotopic liver transplantation. *Gastroenterology* 2001;120:A371.
17. **Befeler A**, Varma CR, Solomon H, Ramrakhiani S. Anemia after orthotopic liver transplantation is common and often due to relative erythropoietin deficiency. *Hepatology* 2001;34:290A
18. Chelamcharla M, Ramrakhiani S, Bacon BR, **Befeler AS**. Do Patients with Hepatitis C and Porphyria Cutanea Tarda Respond to Treatment with Interferon and Ribavirin. *Gastroenterology* 2002;122:P219.
19. **Befeler AS**, Di Bisceglie AM, Marrero J, Chari RS, Afdhal N, Van Thiel D, Roberts L for the Liver Cancer Network. First report from the liver cancer network – A national database of patients with hepatocellular carcinoma. (AASLD Clinical Research Single Topic conference: Hepatocellular Carcinoma September 2003).
20. **Befeler AS**, Marrero JA, Chari RS, Roberts L, Afdhal N, van Thiel D, Di Bisceglie AM. The Epidemiology and survival of patients with hepatocellular carcinoma in the United States: A preliminary report from the Liver Cancer Network. *Hepatology* 2004;40:216A.
21. **Befeler AS**, Dakhil N. Can mycophenolate mofetil be used for autoimmune hepatitis? *Gastroenterology* 2006;

L. CURRENT AND PAST TEACHING RESPONSIBILITIES

Liver Cancer Clinic July 2004 – present
 Post-Liver Transplant Clinic 1998-present
 Continuity Clinic for Gastroenterology Fellows 1998-present
 Endoscopy procedures 1998-present
 Inpatient Gastroenterology Consults and Teaching Rounds 1998-present
 Inpatient Hepatology Consults and Teaching Rounds 1998-present
 Liver Transplantation lecture for preceptors

INVITED PRESENTATIONS

1. **Befeler AS**, Ehrenpreis E, Bissonnette M, Xiao SY. Metastatic gastrinoma presenting as a giant duodenal ulcer with massive upper gastrointestinal bleeding. (Annual meeting of American College of Gastroenterology, November 1997)
2. **Befeler AS**, Schiano TD, Conjeevaram H, Dasgupta KA, Millis JM, Baker AL, Lissos TW. Management of inflammatory bowel disease after liver transplantation. (American Society of Transplant Physicians Annual Scientific Meeting May 1997) (North American Conference of Gastroenterology Fellows)
3. Sponseller C, Ramrakhiani C, **Befeler AS**. Does the Mayo clinic end-stage liver disease model (MELD) accurately allocate organs to 2A patients? (Digestive Disease Week 2001, oral presentation).
4. **Befeler A**, Varma CR, Solomon H, Ramarakhiani S. Anemia after orthotopic liver transplantation is common and often due to relative erythropoietin deficiency. (Digestive Disease Week 2001, poster presentation).
5. Chelamcharla M, Ramrakhiani S, Bacon BR, **Befeler AS**. Do patients with hepatitis c and porphyria cutanea tarda respond to treatment with interferon and ribavirin. (Digestive Disease Week 2002, poster presentation)
6. **Befeler AS**, Di Bisceglie AM, Marrero J, Chari RS, Afdhal N, Van Thiel, Roberts L. For the Liver Cancer Network. First report from the liver cancer network – A national database of patients with hepatocellular carcinoma. (AASLD Clinical Research Single Topic conference: Hepatocellular Carcinoma September 2003, poster).
7. **Befeler AS**, Marrero JA, Chari RS, Roberts L, Afdhal N, van Thiel D, Di Bisceglie AM. Preliminary report from the liver cancer network. (AASLD Plenary session, oral presentation, 2004)
8. Befeler AS. Fostering collaboration across medical disciplines. The hepatologist's perspective. (Building Community Support for Liver Cancer Research – Workshop. January 2007)
9. Befeler AS. Hepatocellular Carcinoma. (University of Iowa Liver Review 2007)
10. Hepatocellular Carcinoma, Screening and Diagnosis. (AASLD Clinical Symposium at Digestive Disease Week 2007)

Revised 10-16-06